AlzeCure to present data from its two main projects at the 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD)
Stockholm, Sweden, October 19, 2017 - AlzeCure Pharma (AlzeCure) today announced that data from its two main projects – NeuroRestore and Alzstatin – will be presented at the 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD) in Boston, MA, USA on November 1 - 4, 2017.All presentations are submitted to a scientific committee and those approved will be able to present their findings, which has to be original data or reinterpretation of data in light of new clinical results. The NeuroRestore project, currently in preclinical development, will be presented by Dr. Pontus